2024 AHAACCAMSSMHRSPACESSCMR Guideline for the Management of Hypertrophic Cardiomyopathy

American College of Cardiology and American Heart Association Release New Guideline

Provides Guidance for Clinicians on the Diagnosis, Treatment, and Management of Hypertrophic Cardiomyopathy

The American College of Cardiology (ACC) and the American Heart Association (AHA) have released the 2024 AHAACCAMSSMHRSPACESSCMR Guideline for the Management of Hypertrophic Cardiomyopathy. This guideline provides comprehensive guidance for clinicians on the diagnosis, treatment, and management of this common genetic heart disease.

Hypertrophic cardiomyopathy is a condition in which the heart muscle becomes abnormally thickened. This can lead to a number of problems, including chest pain, shortness of breath, fatigue, and arrhythmias. In severe cases, hypertrophic cardiomyopathy can lead to heart failure or sudden cardiac death.

The new guideline provides updated recommendations on the diagnosis and treatment of hypertrophic cardiomyopathy. These recommendations are based on the latest scientific evidence and are designed to improve outcomes for patients with this condition.